New Leaf Venture Partners Upped Its Stake in Marinus Pharmaceuticals (MRNS) as Shares Declined; As Scripps E W Co Ohio (SSP) Stock Value Declined, Tealwood Asset Management Trimmed Its Stake by $367,650

May 18, 2018 - By wolcottdaily

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Logo

Robert Boucai increased its stake in Marinus Pharmaceuticals Inc (MRNS) by 70% based on its latest 2017Q4 regulatory filing with the SEC. New Leaf Venture Partners Llc bought 175,000 shares as the company’s stock declined 54.45% with the market. The hedge fund run by Robert Boucai held 425,000 shares of the health care company at the end of 2017Q4, valued at $3.47 million, up from 250,000 at the end of the previous reported quarter. New Leaf Venture Partners Llc who had been investing in Marinus Pharmaceuticals Inc for a number of months, seems to be bullish on the $185.18M market cap company. The stock decreased 2.35% or $0.11 during the last trading session, reaching $4.57. About 395,287 shares traded. Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has risen 130.72% since May 18, 2017 and is uptrending. It has outperformed by 119.17% the S&P500.

Tealwood Asset Management Inc decreased its stake in Scripps E W Co Ohio (SSP) by 15.38% based on its latest 2017Q4 regulatory filing with the SEC. Tealwood Asset Management Inc sold 24,510 shares as the company’s stock declined 23.55% with the market. The institutional investor held 134,875 shares of the broadcasting company at the end of 2017Q4, valued at $2.11 million, down from 159,385 at the end of the previous reported quarter. Tealwood Asset Management Inc who had been investing in Scripps E W Co Ohio for a number of months, seems to be less bullish one the $1.06B market cap company. The stock decreased 0.38% or $0.05 during the last trading session, reaching $13. About 580,125 shares traded or 18.97% up from the average. The E.W. Scripps Company (NYSE:SSP) has declined 46.52% since May 18, 2017 and is downtrending. It has underperformed by 58.07% the S&P500.

Analysts await The E.W. Scripps Company (NYSE:SSP) to report earnings on August, 2. They expect $0.08 earnings per share, 0.00% or $0.00 from last year’s $0.08 per share. SSP’s profit will be $6.54M for 40.63 P/E if the $0.08 EPS becomes a reality. After $-0.10 actual earnings per share reported by The E.W. Scripps Company for the previous quarter, Wall Street now forecasts -180.00% EPS growth.

More important recent The E.W. Scripps Company (NYSE:SSP) news were published by: Globenewswire.com which released: “New Research: Key Drivers of Growth for EW Scripps, Switch, Realogy, The Charles Schwab, CenterPoint Energy, and …” on May 11, 2018, also Seekingalpha.com published article titled: “The EW Scripps’ (SSP) CEO Adam Symson on Q1 2018 Results – Earnings Call Transcript”, Bizjournals.com published: “Cincinnati Bell defeats activist investor” on May 07, 2018. More interesting news about The E.W. Scripps Company (NYSE:SSP) was released by: Bizjournals.com and their article: “Verdict is in on Scripps proxy battle” with publication date: May 10, 2018.

Investors sentiment increased to 1.13 in 2017 Q4. Its up 0.23, from 0.9 in 2017Q3. It increased, as 16 investors sold SSP shares while 39 reduced holdings. 23 funds opened positions while 39 raised stakes. 60.21 million shares or 3.08% less from 62.12 million shares in 2017Q3 were reported. Moreover, Amer Group Inc Inc has 0% invested in The E.W. Scripps Company (NYSE:SSP) for 45,681 shares. Stratos Wealth Prtn has invested 0% in The E.W. Scripps Company (NYSE:SSP). 14,376 were reported by Mason Street Advsrs. Bridgeway Mngmt reported 0.07% stake. Goldman Sachs Gp holds 272,411 shares or 0% of its portfolio. Hall Laurie J Trustee reported 330 shares stake. Keybank National Association Oh holds 0.01% or 72,600 shares in its portfolio. Alphaone Inv Svcs Limited Com stated it has 0.04% of its portfolio in The E.W. Scripps Company (NYSE:SSP). Employees Retirement Association Of Colorado has 13,268 shares for 0% of their portfolio. Barclays Public Ltd stated it has 15,117 shares or 0% of all its holdings. Litespeed Mngmt Llc owns 2.7% invested in The E.W. Scripps Company (NYSE:SSP) for 178,620 shares. Riverhead Mngmt Limited, a Delaware-based fund reported 7,454 shares. Thrivent Finance For Lutherans invested 0% of its portfolio in The E.W. Scripps Company (NYSE:SSP). Landscape Cap Limited Liability stated it has 28,245 shares. Moreover, Sei Invests has 0% invested in The E.W. Scripps Company (NYSE:SSP).

Among 6 analysts covering Scripps (NYSE:SSP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Scripps had 25 analyst reports since August 10, 2015 according to SRatingsIntel. Guggenheim maintained it with “Hold” rating and $18.0 target in Friday, January 26 report. Jefferies maintained the shares of SSP in report on Friday, November 3 with “Hold” rating. The firm earned “Buy” rating on Monday, January 22 by Noble Financial. Stephens initiated the stock with “Equal-Weight” rating in Wednesday, November 18 report. The firm has “Buy” rating by Noble Financial given on Thursday, July 6. The stock of The E.W. Scripps Company (NYSE:SSP) earned “Hold” rating by Jefferies on Monday, June 5. The firm has “Hold” rating given on Monday, August 14 by Jefferies. The firm has “Buy” rating given on Monday, February 27 by Benchmark. The firm earned “Buy” rating on Monday, November 7 by Benchmark. The rating was maintained by Noble Financial on Monday, November 6 with “Buy”.

More news for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) were recently published by: Globenewswire.com, which released: “Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology …” on May 11, 2018. Nasdaq.com‘s article titled: “Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results” and published on May 02, 2018 is yet another important article.

Investors sentiment decreased to 2 in 2017 Q4. Its down 0.80, from 2.8 in 2017Q3. It dropped, as 7 investors sold MRNS shares while 11 reduced holdings. 23 funds opened positions while 13 raised stakes. 20.53 million shares or 8.19% more from 18.97 million shares in 2017Q3 were reported. Susquehanna Group Inc Ltd Liability Partnership reported 0% of its portfolio in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Trexquant LP has invested 0.03% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Price T Rowe Assocs Md has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Millennium Management Ltd Liability Company reported 915,620 shares stake. Granite Point Capital Mgmt Lp has 2.28 million shares. National Bank & Trust Of America Corp De holds 7,312 shares or 0% of its portfolio. Caxton has 0.18% invested in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). State Street accumulated 34,277 shares. 550,000 are held by 683 Cap Mngmt Limited. Cormorant Asset Management Ltd Limited Liability Company has invested 0.43% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Iguana Healthcare Management Ltd has 100,000 shares. Adage Capital Ptnrs Group Limited Com, Massachusetts-based fund reported 567,000 shares. J Goldman Lp has invested 0% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS). Franklin Resource stated it has 2.15M shares or 0.01% of all its holdings. Farallon Capital Lc invested 0.06% in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS).

Since December 15, 2017, it had 0 insider purchases, and 2 insider sales for $10.05 million activity. On Monday, January 29 Smith Edward F sold $23,730 worth of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) or 3,000 shares.

Among 5 analysts covering Marinus Pharmaceuticals (NASDAQ:MRNS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Marinus Pharmaceuticals had 10 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Tuesday, June 14 with “Buy”. The company was maintained on Wednesday, August 10 by Jefferies. The firm earned “Buy” rating on Tuesday, March 8 by Stifel Nicolaus. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) earned “Outperform” rating by Oppenheimer on Wednesday, August 5. The rating was maintained by Oppenheimer with “Outperform” on Friday, October 30. The firm has “Buy” rating given on Monday, March 19 by Mizuho. The firm has “Perform” rating given on Tuesday, June 14 by Oppenheimer. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) earned “Buy” rating by Jefferies on Tuesday, November 17. The stock of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has “Outperform” rating given on Thursday, December 17 by RBC Capital Markets. The firm has “Sector Perform” rating given on Tuesday, June 14 by RBC Capital Markets.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts